Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0140-6736(91)92966-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients.
Clinics (Sao Paulo)
May 2017
Laboratório de Serviços Clínicos e Evidências em Saúde, Departamento de Farmácia, Universidade Federal do Paraná (UFPR), Curitiba, PR, BR.
The aim of this study was to evaluate efficacy and safety of amfepramone, fenproporex and mazindol as a monotherapy for the treatment of obese or overweight patients. A systematic review of primary studies was conducted, followed by a direct meta-analysis (random effect) and mixed treatment comparison. Medline and other databases were searched.
View Article and Find Full Text PDFEffects of pitolisant, a histamine H3 inverse agonist, in drug-resistant idiopathic and symptomatic hypersomnia: a chart review.
Sleep Med
June 2014
National Reference Centre for Narcolepsy and Idiopathic Hypersomnia, France; AP-HP, Hôpital Universitaire Pitié-Salpêtrière, Service des Pathologies du Sommeil, Paris, France; Pierre and Marie Curie University, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière, Inserm U 1127, CNRS UMR7225, Paris, France.
Objective: To evaluate the benefits and risks of pitolisant (a wake-enhancing drug that increases the histamine release in the brain by blocking presynaptic H3 histamine reuptake) in patients with idiopathic (IH) and symptomatic (SH) hypersomnia plus sleepiness refractory to available stimulants (modafinil, methylphenidate, mazindol, sodium oxybate, and d-amphetamine).
Methods: Through retrospective analyses of patient files, the benefit (the score from the Epworth Sleepiness Scale [ESS], authorization renewal) and tolerance (side-effects) of pitolisant were assessed.
Results: A total of 78 patients with IH (n=65%, 78% women) and SH (n=13%, 54% women) received pitolisant 5-50 mg once per day over the course of five days to 37 months.
A comparative study of five centrally acting drugs on the pharmacological treatment of obesity.
Int J Obes (Lond)
August 2014
Endocrine Division (SEMPR), Department of Internal Medicine, Parana Federal University, Curitiba, Brazil.
Context: No long-term studies have compared centrally acting drugs for treating obesity.
Objective: To compare the efficacy and safety of diethylpropion (DEP), fenproporex (FEN), mazindol (MZD), fluoxetine (FXT) and sibutramine (SIB) in promoting weight loss.
Design And Setting: A prospective, randomized, placebo (PCB)-controlled study conducted at a single academic institution.
Long-term cognitive and neurochemical effects of "bath salt" designer drugs methylone and mephedrone.
Pharmacol Biochem Behav
January 2013
Institute of Biomedicine, Pharmacology, Biomedicum Helsinki, Haartmaninkatu 8, FI-00014, University of Helsinki, Finland.
Introduction/aims: The use of cathinone-derivative designer drugs methylone and mephedrone has increased rapidly in recent years. Our aim was to investigate the possible long-term effects of these drugs on a range of behavioral tests in mice. Further, we investigated the long-term effects of these drugs on brain neurochemistry in both rats and mice.
View Article and Find Full Text PDFObjective: Mazindol is a tricyclic, anorectic, non-amphetamine stimulant used in narcolepsy and obesity since 1970. This study aimed to evaluate the long-term benefit/risk ratio in drug-resistant hypersomniacs and cataplexy sufferers.
Methods: By retrospective analysis of the patients' files in the hospitals of Paris-Salpêtrière (n=91), Montpellier (n=40) and Lyon (n=8), the benefit (Epworth Sleepiness Score (ESS), cataplexy frequency, authorization renewal) and tolerance (side-effects, vital signs, electrocardiogram and cardiac echography) of mazindol were assessed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!